Clinical trial
Erythropoietin Therapy to Induce Regulatory T Cells in Liver Transplant Recipients
Name
STU00215838
Description
The hypothesis of this proof-of-concept study is that EPO increases the frequency, stability and/or function of Tregs in liver transplant recipients. We also hypothesize that EPO will have a greater effect in everolimus vs. tacrolimus treated LTR, thus providing the rationale for a subsequent clinical trial to utilize EPO in combination with everolimus as a more successful pathway toward tolerance.
Trial arms
Trial start
2022-02-18
Estimated PCD
2023-05-23
Trial end
2024-09-30
Status
Active (not recruiting)
Phase
Early phase I
Treatment
Erythropoietin
Erythropoietin
Arms:
EPO Arm
Size
9
Primary endpoint
EPO effects on Treg induction
12 weeks
Eligibility criteria
Inclusion Criteria:
* Male or female
* Age 18-74 years
* History of liver transplantation \> 2 years prior for non-immune causes
* Use of immunosuppressive monotherapy (either tacrolimus or everolimus) for treatment of liver transplantation
* Stable immunosuppression regimen at least 3 months prior to enrollment.
* Ability to provide verbal and written informed consent
Exclusion Criteria:
* • Hgb above average normal value (15.7 g/dL in men, 13.8 g/dL in women); ALT \> 2 times upper limit of normal; uncontrolled hypertension with SBP\>160 or DBP\>100; end-stage renal disease on hemodialysis; history of venous thromboembolism including deep vein thromboses or pulmonary emboli, stroke, heart failure, seizure disorder, significant cardiovascular disease including a history of myocardial infarction, pure red cell aplasia, intolerance or allergy to erythropoietin; Active malignancy (untreated or undergoing therapy); known hypersensitivity to mammalian cell-derived products; known hypersensitivity to human albumin; presence of vascular access; prior recipient of erythropoietin within 12 weeks of the study; and pregnancy
* Patient unable to provide consent including infants, children, teenagers, prisoners, cognitively impaired adults.
* Prisoners and other vulnerable populations will also be excluded
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE4'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'HEALTH_SERVICES_RESEARCH', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 9, 'type': 'ACTUAL'}}
Updated at
2024-03-15
1 organization
1 product
1 indication
Organization
Northwestern UniversityProduct
ErythropoietinIndication
Liver Transplant Rejection